The high cost of CAR-T therapies is one of the greatest barriers to access for patients. Data presented at EHA 2022 demonstrate that CAR-T therapies have a high incremental cost compared to chemotherapy despite significant improvements in PFS and OS.
In this study presented at EHA 2022, 1 the patient-reported outcomes of the phase II CARTITUDE-1 were compared to LocoMMotion, a prospective study of real-life standard of care in triple-class exposed patients with relapsed/refractory multiple myeloma treated with real-world clinical practice prior to March 2021.
Real-world evidence data have confirmed the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel). This updated PSM analysis aimed to assess outcomes in a larger cohort of patients with DLBCL over a longer follow-up period.
